Results 261 to 270 of about 9,064,090 (287)

Topical delivery of 5-fluorouracil (5-FU) by 3-alkylcarbonyloxymethyl-5-FU prodrugs

Journal of Pharmaceutical Sciences, 2003
The 3-alkylcarbonyloxymethyl-5-fluorouracil (3-ACOM-5-FU) prodrugs have been characterized by their solubilities in isopropyl myristate (S(IPM)) and partition coefficients between IPM and pH 4.0 buffer (K(IPM:AQ)). Estimated S(AQ) values have been obtained from S(AQ) = S(IPM)/K(IPM:AQ.) The abilities of the prodrugs to deliver total 5-FU species from ...
William J, Roberts, Kenneth B, Sloan
openaire   +2 more sources

Cyclophosphamide plus 5-FU versus 5-FU Alone in Advanced Gastric Carcinoma

Oncology, 2009
30 patients with advanced metastatic gastric adenocarcinoma, having a measurable indicator lesion, were randomized (1:2) to receive (intravenously) either weekly 5-fluorouracil alone (15 mg/kg) or combination treatment with cyclophosphamide (20 mg/kg) given on day 1 and 5-FU (15 mg/kg) given weekly on weeks 2–5, beginning on day 8.
R T, Chlebowski, J M, Weiner, I, Silverberg, A, Glass, J R, Bateman   +4 more
openaire   +2 more sources

Acute Encephalopathy Attributed to 5‐FU

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1996
Acute encephalopathy attributable to 5‐fluorouracil (5‐FU) is rare. A patient experienced this reaction associated with a continuous 5‐FU infusion. The etiology of the event remains uncertain, but it is generally reversible and does not preclude retreatment with 5‐FU at reduced dosages. Steroids and thiamine may expedite neurologic recovery.
C J, Langer, A, Hageboutros, D D, Kloth, D, Roby, A H, Shaer   +4 more
openaire   +2 more sources

Colorectal cancer—Is there an alternative to 5-FU?

European Journal of Cancer, 1997
info:eu-repo/semantics ...
openaire   +3 more sources

Efficacy of adjuvant chemotherapy with 5-Fu/leucovorin and 5-Fu/levamisole in colon cancer

Gastroenterology, 1998
Previous studies have demonstrated the positive impact of adjuvant chemotherapy with 5-FU/levamisole on survival of patients with stage I11 colon cancer. In metastatic cancer, biochemical modulation of 5-FU leads to increased remission rates. Therefore, the effects of 5-FU/leucovorin (450 and 100 mg/m 2 i,v.
R. Porschen, A. Bermann, T. Löffler, G. Haack, K. Rettig, Y. Anger, G. Strohmeyer   +6 more
openaire   +1 more source

Selective delivery of 5-fluorouracil (5-FU) to i.p. tissues using 5-FU microspheres in rats

Anti-Cancer Drugs, 1997
A new formulation has been developed for the delivery of 5-fluorouracil (5-FU) in treating peritoneal carcinomatosis. The new formulation (5-FU-MS) involves the incorporation of 5-FU into microspheres composed of a poly(glycolide-co-lactide) matrix. The incorporated 5-FU is released slowly over a 3 week period. We investigated the drug distribution and
A, Hagiwara, C, Sakakura, H, Tsujimoto, T, Imanishi, M, Ohgaki, J, Yamasaki, K, Sawai, T, Takahashi, T, Fujita, A, Yamamoto, S, Muranishi, Y, Ikada   +11 more
openaire   +2 more sources

Intraoperative Treatment with 5-FU

2018
The use of 5-FU and its effectiveness in the treatment of keloid and hypertrophic scar have been evidenced in several studies reaching very favorable results. Currently, the use has been directed as therapy on healing states with poor evolution already established, where the inhibitory effect of 5-FU on fibroblastic proliferation results in the ...
Guillermo Blugerman, Diego Schavelzon, Roberto Rodrigo Cáceres, Victoria Schavelzon, Miguel Mussi, Guido Blugerman   +5 more
openaire   +1 more source

The noncytotoxic dose of sorafenib sensitizes Bel-7402/5-FU cells to 5-FU by down-regulating 5-FU-induced Nrf2 expression.

Digestive diseases and sciences, 2013
Acquired resistance to 5-fluorouracil (5-FU) is a serious therapeutic obstacle in advanced hepatocellular carcinoma (HCC) patients.To investigate whether nuclear factor erythroid 2-related factor 2 (Nrf2) was associated with drug resistance in 5-FU resistant Bel-7402 (Bel-7402/5-FU) cells, and if sorafenib, an oral multikinase inhibitor targeting the ...
Suna, Zhou, Wenguang, Ye, Xiaoyi, Duan, Mingxin, Zhang, Jiansheng, Wang   +4 more
openaire   +1 more source

Successful treatment with 5-Fu

Ophthalmology, 2003
Barry A, Schechter, Robert S, Nagler
openaire   +2 more sources

[Chemosensitivity testing for 5-FU and 5-FU derivatives using subrenal capsule assay].

Gan to kagaku ryoho. Cancer & chemotherapy, 1987
An evaluation was made, using in vivo subrenal capsule (SRC) assay, of the chemosensitivity of 12 human neoplastic tissues including 7 gastric cancers, 2 colo-rectal cancers, 2 lung cancers and 1 breast cancer, exposed to 5-fluorouracil (5-FU) and the 5-FU derivatives: tegafur (FT), UFT and hexylcarbamoyl-5-FU (HCFU).
H, Anai, Y, Maehara, H, Kusumoto, H, Masuda, K, Sugimachi   +4 more
openaire   +1 more source